2 recruiting, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Terminated 1 |
Follow Primary Peritoneal Clear Cell Adenocarcinoma: new trials by email Literature Review of Primary Peritoneal Clear Cell Adenocarcinoma trials Research Report on Primary Peritoneal Clear Cell Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial Biopsy, Biospecimen Collection, Computed Tomography - Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 78 | 2024-11-12 | 2026-10-02 |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (2)
Adnexal Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Fallopian Tube Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Neoplasms (2) · Neoplasms by Site (2) · Ovarian Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2)
Bevacizumab (2) · Biopsy (2) · Disulfides (2) · Immunoglobulin G (2) · Specimen Handling (2) · Diphtheria Toxoid (1) · Diphtheria-Tetanus Vaccine (1) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1) · Doxorubicin (1) · Gemcitabine (1) · Leukapheresis (1) · Magnetic Resonance Spectroscopy (1) · Paclitaxel (1) · Taxes (1) · Tetanus Toxoid (1)
Mayo Clinic (2) · Roswell Park Cancer Institute (1)
United States (3)
Emese Zsiros (1) · Evanthia Galanis, M.D. (1) · Matthew S. Block, MD, PhD (1)
R01CA267690 (1)